Intravenous
Figure 1: Intravenous administration of ECSOD-mMSCs extends lifespan, retards cataract formation, and prevents carcinogenesis in irradiated mice. (A) Secretion of biologically active ECSOD by ECSOD-mMSCs at various time intervals after transduction. Each value represents mean ± SEM (n=3). (B) Photomicrographs showing expression of nuclear-targeted β-galactosidase by ntlacZ-mMSCs at various time intervals after transduction. Original magnification: 100X. (C) Kaplan-Meier survival curve showing extension of lifespan in irradiated mice treated with ECSOD-mMSCs. P=0.003 by logrank test. (D) Photomicrograph showing delay in cataract formation in irradiated mice treated with ECSOD-mMSCs. Picture was taken 172 days after irradiation. (E) Photomicrograph showing no evidence of carcinogenesis in irradiated mice treated with ECSOD-mMSCs. Picture was taken 449 days after irradiation.